期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 79, 期 9, 页码 917-928出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.12.023
关键词
anticoagulation; clinical trial; coagulopathy; COVID-19
资金
- Amgen
- Novo Nordisk
- Novartis
- Canadian Institutes of Health Research
COVID-19 is associated with thromboembolic disease. Anticoagulation therapy may play a role in patients who do not require intensive care unit support.
Clinical, laboratory, and autopsy findings support an association between coronavirus disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing to a high incidence of thrombosis in large and small blood vessels, both arterial and venous. Observational studies and randomized trials have investigated whether full-dose anticoagulation may improve outcomes compared with prophylactic dose heparin. Although no benefit for therapeutic heparin has been found in patients who are critically ill hospitalized with COVID-19, some studies support a possible role for therapeutic anticoagulation in patients not yet requiring intensive care unit support. We summarize the pathology, rationale, and current evidence for use of anticoagulation in patients with COVID-19 and describe the main design elements of the ongoing FREEDOM COVID-19 Anticoagulation trial, in which 3,600 hospitalized patients with COVID-19 not requiring intensive care unit level of care are being randomized to prophylactic-dose enoxaparin vs therapeutic-dose enoxaparin vs therapeutic-dose apixaban. (FREEDOM COVID-19 Anticoagulation Strategy [FREEDOM COVID]; NCT04512079) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据